Austrália - inglês - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ranvet pty. limited - bicarbonate; nicotinic acid; rutin; calcium; chloride; potassium; magnesium; sodium; phosphate; sulfate; choline; inositol; folic acid; vitamin b12 = cyanocobalamin; vitamin b2 = riboflavin; vitamin b1 = thiamine; vitamin b6 hydrochloride = pyridoxine hydrochloride; vitamin e-d alpha acetate = alpha tocopheryl-d acetate - oral powder, pre-mix - bicarbonate ungrouped active 68.1 g/kg; nicotinic acid alkaloid active 10445.0 mg/kg; rutin flavour active 1766.0 mg/kg; calcium mineral-calcium active 99.0 g/kg; chloride mineral-chlorine active 125.7 g/kg; potassium mineral-potassium active 12.6 g/kg; magnesium mineral-magnesium active 12.8 g/kg; sodium mineral-sodium active 120.0 g/kg; phosphate mineral-phosphorus active 61.5 g/kg; sulfate mineral-sulfur active 42.5 g/kg; choline vitamin-b complex active 7052.0 mg/kg; inositol vitamin-b complex active 8775.0 mg/kg; folic acid vitamin b9 active 816.0 mg/kg; vitamin b12 = cyanocobalamin vitamin-b12 active 14.34 mg/kg; vitamin b2 = riboflavin vitamin-b2 active 3404.0 mg/kg; vitamin b1 = thiamine vitamin-b1 active 3528.0 mg/kg; vitamin b6 hydrochloride = pyridoxine hydrochloride vitamin-b6 active 199.0 mg/kg; vitamin e-d alpha acetate = alpha tocopheryl-d acetate vitamin-e active 3604.0 mg/kg - nutrition & metabolism - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - electrolyte replacement | vitamin b deficiency

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml;  ; potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml - powder for oral suspension - 125 mg/5ml - active: amoxicillin trihydrate 28.698 mg/ml equivalent to amoxycillin 25mg/ml   potassium clavulanate 7.446 mg/ml equivalent to clavulanic acid 6.25mg/ml excipient: aspartame colloidal silicon dioxide golden syrup flavour 52927 ap0551 hydrated silica hypromellose orange flavour phs-134215 orange flavour sd653970 raspberry flavour nn07943 succinic acid xanthan gum - augmentin should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data. augmentin is indicated for the short term treatment of common bacterial infections in adults and children such as: upper respiratory tract infections (including ent): e.g. tonsillitis, sinusitis, otitis media lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar and broncho pneumonia genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections skin and soft tissue infections bone and joint infections: e.g. osteomyelitis other infections: e.g. septic abortion, puerperal sepsis, intra-abdominal sepsis, septicaemia, peritonitis, post-surgical infections susceptibility to augmentin will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. infections caused by amoxicillin susceptible organisms are amenable to augmentin treatment due to its amoxicillin content. mixed infections caused by amoxicillin susceptible organism in conjunction with augmentin susceptible beta-lactamase-producing organisms may therefore be treated by augmentin.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

norton healthcare limited (nz) - carvedilol 3.125mg;  ;   - tablet - 3.125 mg - active: carvedilol 3.125mg     excipient: colloidal silicon dioxide crospovidone iron oxide red iron oxide yellow lactose monohydrate magnesium stearate povidone - carvedilol tablets are indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (eg calcium channel blockers, diuretics).

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

viatris limited - penicillamine 125mg - tablet - 125 mg - active: penicillamine 125mg excipient: glycerol hypromellose microcrystalline cellulose povidone purified water   sodium starch glycolate stearic acid titanium dioxide - severe, active rheumatoid arthritis. as a chelating agent in the treatment of wilson's disease and lead poisoning. d-penamine will enhance the urinary excretion of gold and mercury and other heavy metals. in the treatment of cystinuria in cases where high-fluid regimens are not adequate, or in conjunction with them.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - aprepitant 125mg - capsule - 125 mg - active: aprepitant 125mg excipient: gelatin hyprolose microcrystalline cellulose sodium laurilsulfate sucrose - emend, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of: · moderately emetogenic cancer chemotherapy. · highly emetogenic cancer chemotherapy.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferasirox 125mg;  ;   - dispersible tablet - 125 mg - active: deferasirox 125mg     excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium laurilsulfate - exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

viatris limited - bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg;  ; bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg - film coated tablet - 125 mg - active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg   excipient: glyceryl behenate magnesium stearate maize starch opadry yellow 03k82318 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid active: bosentan monohydrate 129.082mg equivalent to bosentan anhydrous 125 mg excipient: glyceryl behenate magnesium stearate maize starch opadry white 03k580000 povidone sodium laurilsulfate sodium starch glycolate starch surelease clear e-7-19040 as solid - indicated for the treatment of idiopathic pulmonary arterial hypertension, familial pulmonary arterial hypertension, pulmonary arterial hypertension associated with scleroderma or pulmonary arterial hypertension associated with congenital systemic to pulmonary shunts including eisenmenger's physiology in patients with who class iii or iv symptoms.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

haleon new zealand ulc - paracetamol 125mg;  ;  ; paracetamol 125mg - suppository - 125 mg - active: paracetamol 125mg     excipient: gelatin glycerol   macrogol 400 macrogol 6000 methyl hydroxybenzoate propyl hydroxybenzoate titanium dioxide vanillin water active: paracetamol 125mg excipient: gelatin glycerol as excipient and in capsule shell macrogol 400 macrogol 8000 methyl hydroxybenzoate propyl hydroxybenzoate titanium dioxide vanillin water - for fast effective temporary relief of pain and discomfort associated with immunization, earache, cold and flu symptoms, teething and headaches. reduces fever.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

viatris limited - methyldopa sesquihydrate 141.5mg equivalent to to 125 mg methyldopa anhydrous - tablet - 125 mg - active: methyldopa sesquihydrate 141.5mg equivalent to to 125 mg methyldopa anhydrous excipient: citric acid   colloidal silicon dioxide disodium edetate dihydrate ethylcellulose guar gum magnesium stearate opadry yellow oy-8462 purified water sodium starch glycolate - hypertension (mild, moderate or severe).

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 20mg equivalent to 125 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 125µg/25µg - active: fluticasone propionate 20mg equivalent to 125 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.